Advertisement

Angiotensin Receptor Blockers and Cardiovascular Protection: Are We ONTARGET?

      It is well known that activation of the renin-angiotensin system (RAS) plays a crucial role in the initiation and progression of cardiovascular disease (CVD) and target organ damage in patients with hypertension. There is growing recognition that RAS inhibition provides protection against cardiovascular damage, irrespective of blood pressure (BP) levels. Angiotensin-converting enzyme (ACE) inhibitors have been shown to prevent cardiovascular, neurologic, and renal complications in high-risk patients. With the realization that ACE inhibitors do not provide optimal blockade of the RAS, angiotensin receptor blockers (ARBs) have been developed. Although the efficacy of ARBs in the treatment of hypertension is comparable with that of ACE inhibitors, the former class of drugs has not yielded consistent or superior effects on target organ protection. Therefore, an unsettled issue in preventive medicine has been whether ARBs are as effective as (or superior to) ACE inhibitors in high-risk populations.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Yusuf S.
        • Teo K.K.
        • Pogue J.
        • Dyal L.
        • Copland I.
        • Schumacher H.
        • Dagenais G.
        • Sleight P.
        • Anderson C.
        • ONTARGET Investigators
        Telmisartan, ramipril, or both in patients at high risk for vascular events.
        N Engl J Med. 2008; 358: 1547-1559
        • Pfeffer M.A.
        • McMurray J.J.
        • Velazquez E.J.
        • Rouleau J.L.
        • Køber L.
        • Maggioni A.P.
        • Solomon S.D.
        • Swedberg K.
        • Van de Werf F.
        • White H.
        • et al.
        • Valsartan in Acute Myocardial Infarction Trial Investigators
        Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
        N Engl J Med. 2003; 349: 1893-1906
        • Cohn J.N.
        • Tognoni G.
        • Valsartan Heart Failure Trial Investigators
        A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
        N Engl J Med. 2001; 345: 1667-1675
        • McMurray J.J.
        • Ostergren J.
        • Swedberg K.
        • Granger C.B.
        • Held P.
        • Michelson E.L.
        • Olofsson B.
        • Yusuf S.
        • Pfeffer M.A.
        • CHARM Investigators and Committees
        Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.
        Lancet. 2003; 362: 767-771
        • Yusuf S.
        • Sleight P.
        • Pogue J.
        • Bosch J.
        • Davies R.
        • Dagenais G.
        Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.
        N Engl J Med. 2000; 342: 145-153
        • Fox K.M.
        • European Trial on Reduction of Cardiac Events With Perindopril in Stable Coronary Artery Disease Investigators
        Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).
        Lancet. 2003; 362: 782-788
        • Dahlöf B.
        • Devereux R.B.
        • Kjeldsen S.E.
        • Julius S.
        • Beevers G.
        • de Faire U.
        • Fyhrquist F.
        • Ibsen H.
        • Kristiansson K.
        • Lederballe-Pedersen O.
        • et al.
        • LIFE Study Group
        Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension study (LIFE): a randomised trial against atenolol.
        Lancet. 2002; 359: 995-1003
        • PROGRESS Collaborative Group
        Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack.
        Lancet. 2001; 358: 1033-1041
        • Schrader J.
        • Lüders S.
        • Kulschewski A.
        • Hammersen F.
        • Plate K.
        • Berger J.
        • Zidek W.
        • Dominiak P.
        • Diener H.C.
        • MOSES Study Group
        Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES).
        Stroke. 2005; 36: 1218-1226
        • Krum H.
        • Carson P.
        • Farsang C.
        • Maggioni A.P.
        • Glazer R.D.
        • Aknay N.
        • Chiang Y.T.
        • Cohn J.N.
        Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT.
        Eur J Heart Fail. 2004; 6: 937-945
        • Teo K.
        • Yusuf S.
        • Sleight P.
        • Anderson C.
        • Mookadam F.
        • Ramos B.
        • Hilbrich L.
        • Pogue J.
        • Schumacher H.
        • ONTARGET/TRANSCEND Investigators
        Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease (ONTARGET/TRANSCEND) trials.
        Am Heart J. 2004; 148: 52-61
        • Diener H.C.
        • Sacco R.
        • Yusuf S.
        • Steering Committee; PRoFESS Study Group
        Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing 2 antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS).
        Cerebrovasc Dis. 2007; 23: 368-380
        • McMurray J.J.
        • Carson P.E.
        • Komajda M.
        • McKelvie R.
        • Zile M.R.
        • Ptaszynska A.
        • Staiger C.
        • Donovan J.M.
        • Massie B.M.
        Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial.
        Eur J Heart Fail. 2008; 10: 149-156